KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
作者： Maria Debiec-Rychter , Raf Sciot , Axel Le Cesne , Marcus Schlemmer , Peter Hohenberger
DOI: 10.1016/J.EJCA.2006.01.030
关键词:
摘要: … The clinical activity of imatinib has been confirmed in GISTs, both in an … which the highest feasible dose of imatinib was defined as 400 mg twice a day, and in phase II studies with doses …
core.ac.uk
elsevier.com
sci-hub.se 参考文章(24)
S. Lev, D. Givol, Y. Yarden, A specific combination of substrates is involved in signal transduction by the kit-encoded receptor. The EMBO Journal. ,vol. 10, pp. 647- 654 ,(1991) , 10.1002/J.1460-2075.1991.TB07993.X
Maria Debiec-Rychter, Jan Cools, Herlinde Dumez, Raf Sciot, Michel Stul, Nicole Mentens, Hilde Vranckx, Bartosz Wasag, Hans Prenen, Johannes Roesel, Anne Hagemeijer, Allan Van Oosterom, Peter Marynen, Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants Gastroenterology. ,vol. 128, pp. 270- 279 ,(2005) , 10.1053/J.GASTRO.2004.11.020
Heikki Joensuu, Christopher Fletcher, Sasa Dimitrijevic, Sandra Silberman, Peter Roberts, George Demetri, Management of malignant gastrointestinal stromal tumours. Lancet Oncology. ,vol. 3, pp. 655- 664 ,(2002) , 10.1016/S1470-2045(02)00899-9
Anette Duensing, Fabiola Medeiros, Bryna McConarty, Nora E Joseph, Dipak Panigrahy, Samuel Singer, Christopher DM Fletcher, George D Demetri, Jonathan A Fletcher, Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs) Oncogene. ,vol. 23, pp. 3999- 4006 ,(2004) , 10.1038/SJ.ONC.1207525
Allan T van Oosterom, Ian Judson, Jaap Verweij, Sigrid Stroobants, Eugenio Donato di Paola, Sasa Dimitrijevic, Marc Martens, Andrew Webb, Raf Sciot, Martine Van Glabbeke, Sandra Silberman, Ole S Nielsen, Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. The Lancet. ,vol. 358, pp. 1421- 1423 ,(2001) , 10.1016/S0140-6736(01)06535-7
Marcia L. Lux, Brian P. Rubin, Tara L. Biase, Chang-Jie Chen, Timothy Maclure, George Demetri, Sheng Xiao, Samuel Singer, Christopher D.M. Fletcher, Jonathan A. Fletcher, KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. American Journal of Pathology. ,vol. 156, pp. 791- 795 ,(2000) , 10.1016/S0002-9440(10)64946-2
Michael C. Heinrich, Brian P. Rubin, B.Jack Longley, Jonathan A. Fletcher, Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations Human Pathology. ,vol. 33, pp. 484- 495 ,(2002) , 10.1053/HUPA.2002.124124
Christopher D.M. Fletcher, Heikki Joensuu, George D. Demetri, Margaret von Mehren, Charles D. Blanke, Annick D. Van den Abbeele, Burton Eisenberg, Peter J. Roberts, Michael C. Heinrich, David A. Tuveson, Samuel Singer, Milos Janicek, Jonathan A. Fletcher, Stuart G. Silverman, Sandra L. Silberman, Renaud Capdeville, Beate Kiese, Bin Peng, Sasa Dimitrijevic, Brian J. Druker, Christopher Corless, Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. The New England Journal of Medicine. ,vol. 347, pp. 472- 480 ,(2002) , 10.1056/NEJMOA020461
Brian J. Druker, Shu Tamura, Elisabeth Buchdunger, Sayuri Ohno, Gerald M. Segal, Shane Fanning, Jürg Zimmermann, Nicholas B. Lydon, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Medicine. ,vol. 2, pp. 561- 566 ,(1996) , 10.1038/NM0596-561
Rosemarie Mick, John J Crowley, Raymond J Carroll, Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint. Controlled Clinical Trials. ,vol. 21, pp. 343- 359 ,(2000) , 10.1016/S0197-2456(00)00058-1